Fusion Antibodies plc (LON:FAB – Get Free Report) insider Adrian Kinkaid purchased 83,728 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was purchased at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,373.36).
Adrian Kinkaid also recently made the following trade(s):
- On Wednesday, September 4th, Adrian Kinkaid purchased 120,000 shares of Fusion Antibodies stock. The stock was purchased at an average price of GBX 3 ($0.04) per share, for a total transaction of £3,600 ($4,700.97).
Fusion Antibodies Price Performance
Shares of LON:FAB opened at GBX 4.90 ($0.06) on Thursday. The firm’s 50 day moving average is GBX 3.61 and its two-hundred day moving average is GBX 3.51. Fusion Antibodies plc has a 52 week low of GBX 2.80 ($0.04) and a 52 week high of GBX 9.50 ($0.12). The firm has a market capitalization of £4.67 million, a P/E ratio of -120.00 and a beta of 0.49. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40.
Fusion Antibodies Company Profile
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.
Featured Articles
- Five stocks we like better than Fusion Antibodies
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Stock Splits, Do They Really Impact Investors?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is a Low P/E Ratio and What Does it Tell Investors?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.